BioLine Rx (XTAE:BLRX) Cash-to-Debt : 3.71 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BioLine Rx's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.71.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BioLine Rx could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for BioLine Rx's Cash-to-Debt or its related term are showing as below:

XTAE:BLRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.63 Med: 8.22 Max: No Debt
Current: 3.71

During the past 13 years, BioLine Rx's highest Cash to Debt Ratio was No Debt. The lowest was 2.63. And the median was 8.22.

XTAE:BLRX's Cash-to-Debt is ranked worse than
58.91% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs XTAE:BLRX: 3.71

BioLine Rx Cash-to-Debt Historical Data

The historical data trend for BioLine Rx's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioLine Rx Cash-to-Debt Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.63

2.94

12.29

4.15

3.71

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															4.15	3.36	2.42	1.95	3.71

Competitive Comparison of BioLine Rx's Cash-to-Debt

For the Biotechnology subindustry, BioLine Rx's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Cash-to-Debt falls into.

BioLine Rx Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BioLine Rx's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	160.782	/	(13.736	+	29.611)
	=	3.71

BioLine Rx's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	160.782	/	(13.736	+	29.611)
	=	3.71

BioLine Rx (XTAE:BLRX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BioLine Rx Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.